137 related articles for article (PubMed ID: 9807740)
1. Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation.
Or R; Ackerstein A; Nagler A; Amar A; Naparstek E; Varadi G; Kapelushnik J; Samuel S; Pugatsch T; Brautbar C; Slavin S
J Immunother; 1998 Nov; 21(6):447-53. PubMed ID: 9807740
[TBL] [Abstract][Full Text] [Related]
2. Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants.
Slavin S; Nagler A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S59-67. PubMed ID: 9457396
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study.
Or R; Ackerstein A; Nagler A; Kapelushnik J; Naparstek E; Samuel S; Amar A; Bruatbar C; Slavin S
Cytokines Cell Mol Ther; 1998 Mar; 4(1):1-6. PubMed ID: 9557210
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
[TBL] [Abstract][Full Text] [Related]
6. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy.
Weiss L; Reich S; Slavin S
Cancer Invest; 1992; 10(1):19-26. PubMed ID: 1735011
[TBL] [Abstract][Full Text] [Related]
7. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma.
Slavin S; Nagler A
Ann Oncol; 1998; 9 Suppl 1():S31-9. PubMed ID: 9581239
[TBL] [Abstract][Full Text] [Related]
9. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
10. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Samuel S; Kapelushnik J; Brautbar C; Or R
Blood; 1996 Mar; 87(6):2195-204. PubMed ID: 8630379
[TBL] [Abstract][Full Text] [Related]
12. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
Slavin S; Morecki S; Weiss L; Or R
J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
[TBL] [Abstract][Full Text] [Related]
13. Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia.
Weiss L; Nusair S; Reich S; Sidi H; Slavin S
Cancer Immunol Immunother; 1996 Oct; 43(2):103-8. PubMed ID: 8954144
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT).
Slavin S; Or R; Kapelushnik Y; Drakos P; Ackerstein A; Vourka-Karussis U; Weiss L; Nagler A
Leukemia; 1992 Nov; 6 Suppl 4():164-6. PubMed ID: 1434823
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines.
Slavin S; Ackerstein A; Weiss L; Nagler A; Or R; Naparstek E
Cancer Invest; 1992; 10(3):221-7. PubMed ID: 1581831
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation.
Nagler A; Ackerstein A; Or R; Naparstek E; Slavin S
Exp Hematol; 2000 Nov; 28(11):1225-31. PubMed ID: 11063870
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies.
Fefer A; Robinson N; Benyunes MC; Bensinger WI; Press O; Thompson JA; Lindgren C
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S48-53. PubMed ID: 9457394
[TBL] [Abstract][Full Text] [Related]
20. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders.
Ackerstein A; Kedar E; Slavin S
Blood; 1991 Sep; 78(5):1212-5. PubMed ID: 1878588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
